Skip to content

The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer

A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01833650
Enrollment
120
Registered
2013-04-17
Start date
2018-02-01
Completion date
2024-08-01
Last updated
2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Keywords

thyroid cancer, radioiodine treatment, xerostomia, sialadenitis

Brief summary

The purpose of this study is to determine whether the use of honey mouthwashes in the prevention of salivary side effects of 131I (radioiodine) therapy.

Interventions

DIETARY_SUPPLEMENTthymus honey mouthwash

Based on the intervention, each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.

Sponsors

Cyprus University of Technology
Lead SponsorOTHER
Bank of Cyprus Oncology Centre
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* \>18 years old * They had a histological diagnosis of papillary, follicular, medullary or anaplastic thyroid cancer * They had undergone total thyroidectomy * They were able to provide consent

Exclusion criteria

* patients who had distant metastases, * a history of salivary-gland disorders, * collagen tissue disease * diabetes mellitus, * previous radioiodine therapy or external radiation to the head or neck * allergy to the honey

Design outcomes

Primary

MeasureTime frame
Grade of sialadenitisChange from Baseline grade of sialadenitis at 6 and 24 months

Secondary

MeasureTime frame
Grade of XerostomiaChange from Baseline grade of xerostomia at 6 and 24 months
Level of Health related quality of lifeChange from Baseline level of health related quality of life at 6 and 24 months

Countries

Cyprus

Contacts

PRINCIPAL_INVESTIGATORAndreas Charalambous, PhD

Cyprus University of Technology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026